“…The increased expression of CD177 and CEACAM1 genes, markers of neutrophils activation, were found associated with gastrointestinal toxicity occurrence ( 33 ). Similarly, using whole-blood RNA transcript-based models from a169-gene panel, a 16-gene signature (including CARD12, CCL3, CCR3, CXCL1, F5, FAM210B, GADD45A, IL18bp, IL2RA, IL5, IL8, MMP9, PTGS2, SOCS3, TLR9, and UBE2C) was identified to be predictive of tremelimumab-related gastrointestinal toxicities as well as to discriminate patients developing grade 0–1 from grade 2–4 diarrhea/colitis ( 34 ).…”